Hosted on MSN3d
BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Nature1y
Innovating highly differentiated gene and cell therapies targeting patients with high unmet need
In common with UltraCAR-T, Precigen’s AdenoVerse Immunotherapy platform is poised to disrupt the gene therapy space. The AdenoVerse platform is differentiated from other gene therapies ...
pharmaphorum9d
Study of Vicore's DTx for anxiety in IPF patients gets underway
If approved, Almee could form part of a differentiated therapy offering for IPF patients alongside Vicore's drug candidates for IPF. Its pipeline is currently headed by VP01 (also known as C21 ...